BIM
BMRN icon

BlackRock Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

BlackRock Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$8.98M Buy
108,401
+22,139
+26% +$1.9M 0.01% 1187
2016
Q3 		$7.98M Buy
86,262
+1,648
+2% +$155K 0.01% 1150
2016
Q2 		$6.58M Sell
84,614
-1,718
-2% -$146K 0.01% 1239
2016
Q1 		$7.12M Sell
86,332
-2,770
-3% -$225K 0.01% 1140
2015
Q4 		$9.33M Sell
89,102
-132
-0.1% -$13.8K 0.01% 979
2015
Q3 		$9.4M Sell
89,234
-16,055
-15% -$2.14M 0.01% 965
2015
Q2 		$14.4M Sell
105,289
-2,546
-2% -$316K 0.02% 748
2015
Q1 		$13.4M Buy
107,835
+4,655
+5% +$493K 0.02% 769
2014
Q4 		$9.33M Sell
103,180
-12,603
-11% -$1.05M 0.01% 988
2014
Q3 		$8.36M Buy
115,783
+9,902
+9% +$651K 0.01% 1032
2014
Q2 		$6.59M Buy
105,881
+46,756
+79% +$2.82M 0.01% 1224
2014
Q1 		$4.03M Buy
59,125
+4,462
+8% +$329K 0.01% 1531
2013
Q4 		$3.85M Sell
54,663
-852
-2% -$57.9K 0.01% 1538
2013
Q3 		$4.01M Buy
55,515
+11,168
+25% +$742K 0.01% 1432
2013
Q2 		$2.47M Buy
+44,347
New +$2.76M ﹤0.01% 1706

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's BMRN Position: Q4 2016 in Review

BlackRock Investment Management increased its BioMarin Pharmaceuticals (BMRN) stake by 26% in Q4 2016, buying an estimated $1.9M and bringing the position to 108,401 shares worth $8.98M. The position accounts for 0.01% of the portfolio, ranked #1187.

BlackRock Investment Management first reported a position in BMRN in Q2 2013 and has held it in 15 quarters since. The position peaked at $14.4M in Q2 2015. 414 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • BlackRock Investment Management held 108,401 shares of BioMarin Pharmaceuticals worth $8.98M as of Q4 2016.
  • BlackRock Investment Management bought 22,139 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $1.9M.
  • BioMarin Pharmaceuticals made up 0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1187 holding.
  • BlackRock Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's BioMarin Pharmaceuticals position peaked at $14.4M in Q2 2015.
  • 414 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.